Advertisement

Clinical Pharmacokinetics

, Volume 8, Issue 6, pp 523–529 | Cite as

Clinical Pharmacokinetics of Metoclopramide

  • D. Nicholas Bateman
Review Article

Summary

Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and in man undergoes variable first-pass metabolism (oral bioavailability 32 to 100%). In man, N-4 sulphate conjugation is an important pathway of metabolism and after oral administration the ratio of free to conjugated metoclopramide in urine correlates with the plasma AUC.

The elimination half-life of metoclopramide is dose-dependent after both intravenous and oral administration of single doses between 5 and 20mg. Metabolic profiles in animal species studied are very different from man. The clearance of metoclopramide is reduced in patients with renal failure to approximately 50% of normals and the terminal half-life is prolonged; this is despite the fact that renal clearance of free drug accounts for only 20% of the administered dose in normals.

Preliminary studies after ‘high dose’ metoclopramide demonstrate accumulation to high plasma concentrations with linear kinetics, suggesting that current high dose regimens are unnecessarily cumbersome.

Keywords

Clinical Pharmacology Metoclopramide Clinical Pharmacokinetic Total Body Clearance Liver Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arita, T.: Hori, R.; Ito, K.; Ichikawa, K. and Uesugi, T.: Transformation and, excretion of drugs in biological system, II. Transformation of metoclopramide in rabbits. Chemical and Pharmaceutical Bulletin 18: 1663–1669 (1970a).CrossRefGoogle Scholar
  2. Arita, T.; Hori, R.; Ito, K. and Ichikawa, K.: Transformation and excretion of drugs in biological systems. III. Separatory determination of metoclopramide and its N4 glucuronide and N4 sulphonate in rabbit urine and bile. Chemical and Pharmaceutical Bulletin 18: 1670–1674 (1970b).CrossRefGoogle Scholar
  3. Arita, T.: Hori, R.; Ito, K. and Sekikawa, H.: Transformation and excretion of drugs in biological systems. IV. Reabsorption of biliary metoclopramide-N4 glucuronide and N4 sulfonate from rabbit intestine. Chemical and Pharmaceutical Bulletin 18: 1675–1679 (1970c).CrossRefGoogle Scholar
  4. Bakke, O.M. and Segura, J.: The absorption and elimination of metoclopramide in three animal species. Journal of Pharmacy and Pharmacology 28: 32–39 (1976).PubMedCrossRefGoogle Scholar
  5. Bateman, D.N.: Clinical pharmacological studies on metoclopramidc. (MD Thesi, University of London 1978).Google Scholar
  6. Bateman, D.N.: Pharmacokinetics and metabolism of the benzamides; in Stanley and Retrosen (Eds) The Benzamides: Pharmacolog, Neurobiology and Clinical Aspects. Advances in Biochemical Psychopharmacolog, Vol. 35, pp. 143–162 (Raven Pres, New York 1982).Google Scholar
  7. Baleman, D.N.: Craft, A.W.; Nicholson, E. and Pearson, A.D.J.: Dystonic reaction and the pharmacokinetics of metoclopramide in children. British Journal of Clinical Pharmacology 15: 560–563 (1983b).CrossRefGoogle Scholar
  8. Bateman, D.N. and Davies, D.S.: Pharmacokinetics of metoclopramide. Lancet 1: 166 (1979).PubMedCrossRefGoogle Scholar
  9. Bateman, D.N.; Gokal, R.; Dodd, T.R.P. and Blain, P.G.: The pharmacokinetics of single doses of metoclopramide in renal failure. European Journal of Clinical Pharmacology 19: 437–441 (1981).PubMedCrossRefGoogle Scholar
  10. Bateman, D.N.; Kahn, C.: and Davies, D.S.: Concentration effect studies with oral metoclopramide. British Journal of Clinical Pharmacology 8: 179–182 (1979).PubMedCrossRefGoogle Scholar
  11. Bateman, D.N.; Kahn, C. and Davies, D.S.: The pharmacokinetics of meloclopramide in man with observations in the dog. British Journal of Clinical Pharmacology 9: 371–377 (1980).PubMedCrossRefGoogle Scholar
  12. Bateman, D.N.; Kahn, C.; Legg, N.J. and Reid, J.L.: Metoclopramide in Parkinson’s disease. Clinical Pharmacology and Therapeutics 24: 459–464 (1978a).PubMedGoogle Scholar
  13. Bateman, D.N.: Kahn, C.; Mashiter, K. and Davies, D.S.: Pharmacokinetics and concentration-effect studies with intravenous metoclopramide. British Journal of Clinical Pharmacology 6: 401–407 (1978b).PubMedCrossRefGoogle Scholar
  14. Bateman, D.N.; Procter, S.J.; Rawlins, N.D. and Taylor, W.B.: Kinetics and efficacy of high-dose metoclopramide used in the prevention of cytotoxic-induced nausea and vomiting. British Journal of Pharmacology 79: 490P (1983a).Google Scholar
  15. Block, W.; Pingoud, A.; Khan, M. and Kjellerup, P.: The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. Arzneimittel-Forschung 31: 1041–1045 (1981).PubMedGoogle Scholar
  16. Caralps, A.: Metoclopramide and renal failure. Lancet 1: 554 (1979).PubMedCrossRefGoogle Scholar
  17. Casteels-van Daele, M.; Jaeken, J.; van Der Schueren, P.; Zimmerman, A. and van Den Bon, P.: Dystonic reactions in children caused by metoclopramide. Archives of Disease in Childhood 45: 130–133 (1970).PubMedCrossRefGoogle Scholar
  18. Cowan, D.A.; Huizing, G. and Beckett, A.H.: Identification of four new metabolic products of metoclopramide using mass spectrometry. Xenobiotica 6: 605–616 (1976).PubMedCrossRefGoogle Scholar
  19. Graffner, C.; Lagerstrom, P.-O.; Lundborg, P. and Ronn, A.: Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. British Journal of Clinical Pharmacology 8: 469–474 (1979).PubMedCrossRefGoogle Scholar
  20. Gralla, R.J.; Itri, L.M.; Pisko, S.E.; Squilante, A.E.; Kelsen, D.P.; Braun, D.W.; Bordin, L.A.; Braun, T.J. and Young, C.W.: Antiemetic efficacy of high-dose metoclopramide: Randomised trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New England Journal of Medicine 305: 905–909 (1981).PubMedCrossRefGoogle Scholar
  21. Harrington, R.A.; Hamilton, C.W.; Brodgen, R.N.; Linkewich, J.A.; Romankiewicz, J.A. and Heel, R.C.: Metoclopramide: An update review of its pharmacological properties and clinical use. Drugs 25: 451–494 (1983).PubMedCrossRefGoogle Scholar
  22. Hay, A.M.: Pharmacological analysis of the effects of metoclopramide on the guinea pig isolated stomach. Gastroenterology 72: 864–869 (1977).PubMedGoogle Scholar
  23. Hucker, M.B.; Hochberg, A.; Hoffman, E.A. and Miller, J.K.: Studies on the physiological disposition of metoclopramide. Pharmacologist 8: 220 (1966).Google Scholar
  24. Justin-Besançon, L.; Laville, C. and Thominet, M.: Le metoclopramide et ses homologues. Introduction a leur étude biologique. Comptes Rendus des Seances de l’Acadamie des Sciences (Paris) 258: 4384–4386 (1964).Google Scholar
  25. Lavy, S.; Melamed, E. and Penchas, S.: Tardive dyskinesia associated with metoclopramide. British Medical Journal 1: 77–78 (1978).PubMedCrossRefGoogle Scholar
  26. Moertel, C.G. and Reitemeier, R.J.: Controlled clinical studies with orally administered antiemetic drugs. Gastroenterology 57: 262–268 (1969).PubMedGoogle Scholar
  27. Morran, C.; Smith, D.C.; Anderson, D.A. and McArdle, C.S.: Evidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of anti-emetics. British Medical Journal 1323: 324 (1979).Google Scholar
  28. Pinder, R.M.; Brogden, R.M.; Sawyer, P.R.; Speight, T.M. and Avery, G.S.: Metoclopramide: A review of its pharmacological properties and clinical use. Drugs 12: 81–131 (1976).PubMedCrossRefGoogle Scholar
  29. Ross-Lee, L.M.; Eadie, M.J.; Hooper, W.D. and Bochner, F.: Single-dose pharmacokinetics of metoclopramide. European Journal of Clinical Pharmacology 20: 465–471 (1981).PubMedCrossRefGoogle Scholar
  30. Schulze-Delrieu, K.: Metoclopramide. New England Journal of Medicine 305: 28–32 (1981).PubMedCrossRefGoogle Scholar
  31. Strum, S.B.; McDermed, J.E.; Opfell, R.W. and Riech, L.P. Intravenous metoclopramide an effective anti-emetic in cancer chemotherapy. Journal of the American Medical Association 247: 2683–2686 (1982).PubMedCrossRefGoogle Scholar
  32. Tarn, Y.K.; Axelson, J.E. and Ongley, R.: Modification of metoclopramide GLC assay: Application to human biological specimens. Journal of Pharmaceutical Sciences 68: 1254–1256 (1979).CrossRefGoogle Scholar
  33. Tarn, Y.K.; Axelson, J.E.; McErlane, B.; Ongley, R. and Price, J.D.E.: Dose-dependent pharmacokineties of metoclopramide in rat: An effect of hemoperfusion? Journal of Pharmacology and Experimental Therapeutics 217: 764–769 (1981a).Google Scholar
  34. Tarn, Y.K.; Axelson, J.E.; McErlane, B.; Kapil, R.P.; Riggs, K.W.; Ongley, R. and Price, J.D.E.: The pharmacokinetics of metoclopramide in rats with experimental renal and hepatic dysfunction. Journal of Pharmacology and Experimental Therapeutics 219: 141–146 (1981b).Google Scholar
  35. Taylor, W.; Rawlins, M.D. and Bateman, D.N.: High dose metoclopramide — Preliminary pharmacokinetic studies. British Journal of Clinical Pharmacology 16: 341–342 (1983).PubMedCrossRefGoogle Scholar
  36. Teng, L.; Bruce, R.B. and Dunning, L.K.: Metoclopramide metabolism and determination by high-pressure liquid chromatography. Journal of Pharmaceutical Sciences 66: 1615–1618 (1977).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1983

Authors and Affiliations

  • D. Nicholas Bateman
    • 1
  1. 1.Wolfson Unit of Clinical PharmacologyThe University of Newcastle upon TyneNewcastle upon TyneEngland

Personalised recommendations